HC Wainwright Has Pessimistic Outlook of MLTX Q1 Earnings

Chronological Source Flow
Back

AI Fusion Summary

HC Wainwright revised earnings forecasts for three biopharma firms, lowering Q3 2026 estimates for Harrow and Q1 2026 estimates for MoonLake Immunotherapeutics, while raising its FY2026 outlook for Compass Pathways.
06/03 08:03 defenseworld.net
3 Πηγές
06/03 08:26 defenseworld.net
06/03 08:26 defenseworld.net
Comments
Loading...
0